X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
index medicus (40) 40
female (38) 38
male (36) 36
chemistry (34) 34
metallurgy (34) 34
oncology (34) 34
middle aged (31) 31
human necessities (29) 29
aged (28) 28
performing operations (26) 26
transporting (26) 26
lung cancer (22) 22
adult (21) 21
lung neoplasms - drug therapy (19) 19
mutation (17) 17
chemotherapy (16) 16
physics (16) 16
aged, 80 and over (15) 15
gefitinib (14) 14
paper (14) 14
textiles (14) 14
animals (13) 13
braiding (13) 13
cancer (13) 13
knitting (13) 13
lace-making (13) 13
lung neoplasms - genetics (13) 13
lung neoplasms - pathology (13) 13
non-woven fabrics (13) 13
trimmings (13) 13
carcinoma, non-small-cell lung - drug therapy (12) 12
receptor, epidermal growth factor - genetics (12) 12
respiratory system (12) 12
analysis (11) 11
baby linen (11) 11
characteristic features of footwear (11) 11
footwear (11) 11
handkerchiefs (11) 11
indexing scheme associated with sublasses of section d, relating to textiles (11) 11
indexing scheme associated with sublasses of sectiond, relating totextiles (11) 11
parts of footwear (11) 11
shirts (11) 11
underwear (11) 11
wearing apparel (11) 11
measuring (10) 10
neoplasm staging (10) 10
testing (10) 10
agriculture (9) 9
animal husbandry (9) 9
chemical surface treatment (9) 9
coating by vacuum evaporation, by sputtering, by ion implantationor by chemical vapour deposition, in general (9) 9
coating by vacuum evaporation, by sputtering, by ionimplantation or by chemical vapour deposition, in general (9) 9
coating material with metallic material (9) 9
coating metallic material (9) 9
diffusion treatment of metallic material (9) 9
docetaxel (9) 9
fishing (9) 9
forestry (9) 9
hunting (9) 9
inhibiting corrosion of metallic material or incrustation ingeneral (9) 9
surface treatment of metallic material by diffusion into thesurface, by chemical conversion or substitution (9) 9
therapy (9) 9
trapping (9) 9
beer (8) 8
biochemistry (8) 8
care of birds, fishes, insects (8) 8
enzymology (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
microbiology (8) 8
mutation or genetic engineering (8) 8
new breeds of animals (8) 8
pulmonary/respiratory (8) 8
rearing or breeding animals, not otherwise provided for (8) 8
retrospective studies (8) 8
spirits (8) 8
vinegar (8) 8
wine (8) 8
carcinoma, non-small-cell lung - mortality (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
case report (7) 7
conveying (7) 7
expression (7) 7
genetic aspects (7) 7
handling thin or filamentary material (7) 7
investigating or analysing materials by determining theirchemical or physical properties (7) 7
lung neoplasms - mortality (7) 7
mice (7) 7
packing (7) 7
patients (7) 7
producing particular articles from plastics or from substancesin a plastic state (7) 7
protein kinase inhibitors - therapeutic use (7) 7
storing (7) 7
treatment outcome (7) 7
trial (7) 7
working of plastics (7) 7
working of substances in a plastic state, in general (7) 7
acquired-resistance (6) 6
cancer therapies (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (212) 212
Japanese (20) 20
French (9) 9
German (6) 6
Chinese (2) 2
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 353 - 358
Circulating tumor DNA (ctDNA) is an emerging field of cancer research. For lung cancer, non‐invasive genotyping of EGFR is the foremost application. The... 
lung cancer | Carcinoembryonic antigen | epidermal growth factor receptor tyrosine kinase inhibitor | massively parallel DNA sequencer | circulating tumor DNA | Epidermal growth factor receptor tyrosine kinase inhibitor | Massively parallel DNA sequencer | Lung cancer | Circulating tumor DNA | GEFITINIB | PLASMA DNA | ACQUIRED-RESISTANCE | EGFR MUTATIONS | EMERGENCE | CELL LUNG-CANCER | HETEROGENEITY | THERAPY | ONCOLOGY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Mutation, Missense | Biomarkers, Tumor - blood | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Tyrosine | Development and progression | Epidermal growth factor | Multiprocessing | Analysis | DNA | Phenols | Genetic research | Genetic aspects | Nucleotide sequencing | CEA (Oncology) | Cancer | DNA sequencing | Plasma | Disease | Laboratories | Cytotoxicity | Gene deletion | Kinases | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Subpopulations | Nucleotide sequence | Epidermal growth factor receptors | Invasiveness | Patients | Studies | Genotyping | Biopsy | Mutation | Genetic testing | Cytotoxic agents | Tumors | Original
Journal Article
by Yamagami, Keitaro and Kurogi, Ryota and Kurogi, Ai and Nishimura, Kunihiro and Onozuka, Daisuke and Ren, Nice and Kada, Akiko and Nishimura, Ataru and Arimura, Koichi and Ido, Keisuke and Mizoguchi, Masahiro and Sakamoto, Tetsuya and Kayama, Takamasa and Suzuki, Michiyasu and Arai, Hajime and Hagihara, Akihito and Iihara, Koji and Takigami, Masayoshi and Kamiyama, Kenji and Houkin, Kiyohiro and Nishi, Shougo and Yoshimoto, Tetsuyuki and Kaneko, Sadao and Oka, Koji and Ooyama, Hiroshi and Kamada, Kyousuke and Makino, Kenichi and Tokumitsu, Naoki and Sako, Kazuhiro and Suzuki, Susumu and Suzuki, Nozomi and Izumi, Naoto and Nitta, Kazumi and Ootaki, Masahumi and Isobe, Masanori and Nishiya, Mikio and Yamazaki, Takaaki and Mabuchi, Syouji and Ogasawara, Kuniaki and Kubo, Naohiko and Shimizu, Yukihiko and Saito, Keiichi and Yamanome, Tatumi and Yoshino, Atsuo and Fujitsuka, Mitsuyuki and Takami, Masaaki and Ohtaka, Hirotoshi and Hirano, Teruyuki and Shiokawa, Yosiaki and Okada, Takaharu and Suzuki, Ichiro and Kohno, Michihiro and Haraoka, Jou and Arai, Yoshinori and Kawamura, Noriyoshi and Isoshima, Akira and Yasue, Masaharu and Takayoshi Kobayashi, Mitsuhiko Hokari and Kawai, Kensuke and Maehara, Taketoshi and Arai, Hajime and Noguchi, Makoto and Hoshino, Haruhiko and Hiyama, Hirofumi and Yoshida, Kensaku and Utsugi, Osamu and Takeda, Yasuaki and Tamaki, Kouichi and Karasudani, Hirohide and Urabe, Takao and Kobayashi, Shiro and Nakamura, Michio and Koguchi, Yorio and Ono, Junichi and Suda, Sumio and Hadeishi, Hiromu and Fukutake, Toshio and Wakui, Kenji and Tanno, Hirokazu and Ishige, Naoki and Ohasi, Takashi and Sakai, Hideki and Nishimura, Yasuaki and Watanabe, Takayuki and Matsumoto, Takashi and Koketsu, Naoki and Hirose, Yuichi and Doyu, Manabu and Hasegawa, Toshinori and Kuwayama, Naoto and Terao, Shinichi and Mizutani, Nobuhiko and Suzaki, Noriyuki and Okuda, Satoshi and Yasui, Keizo and Seki, Yukio and Hasegawa, Yasuhiro and Ikeda, Akira and Takeuchi, Youtarou and Ohara, Sigeki and ... and J-ASPECT Study Collaborators
World Neurosurgery, ISSN 1878-8750, 10/2019, Volume 130, pp. e26 - e46
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e81468
The detection of rare mutants using next generation sequencing has considerable potential for diagnostic applications. Detecting circulating tumor DNA is the... 
GROWTH-FACTOR RECEPTOR | GEFITINIB | CIRCULATING TUMOR DNA | RARE MUTATIONS | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | EGFR MUTATIONS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Reproducibility of Results | Humans | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Sensitivity and Specificity | Alleles | Antineoplastic Agents - pharmacology | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Mutation | Lung Neoplasms - diagnosis | Allelomorphism | Technology application | Epidermal growth factor | Gene mutations | Lung cancer | Analysis | DNA | Genetic aspects | Cancer | Oncology | Statistical methods | Kinases | Cancer therapies | Gene sequencing | Protein-tyrosine kinase receptors | Mathematical models | Bioinformatics | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Hypothesis testing | Tyrosine | Statistical analysis | Epidermal growth factor receptors | Decision making | Data processing | Decision analysis | Disease control | Mutants | Statistical models | Biopsy | Samples | Diagnostic software | Error detection | Diagnostic systems | Anomalies | DNA sequencing | Deoxyribonucleic acid
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 07/2019, Volume 39, Issue 7, pp. 3923 - 3929
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring EGFR mutation; however, treatment... 
1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | SENSITIVITY | T790M | OPEN-LABEL | CHEMOTHERAPY | EGFR mutation | CELL LUNG-CANCER | EVOLUTION | Afatinib | ONCOLOGY | sequential TKI-therapy | osimertinib | MUTATION | INHIBITORS | Tyrosine | Heterogeneity | Epidermal growth factor receptors | Non-small cell lung carcinoma | Mutation | Gefitinib | Kinases | Patients | Protein-tyrosine kinase
Journal Article
Long Range Planning, ISSN 0024-6301, 04/2010, Volume 43, Issue 2-3, pp. 364 - 369
A 'business model' is commonly seen as composed of two elements: a business system and a profit model. While the latter often gains the higher profile, the... 
BUSINESS | MANAGEMENT | PLANNING & DEVELOPMENT
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2018, Volume 36, Issue 6, p. 1138
Pembrolizumab, a humanized monoclonal immunoglobulin (Ig) G4 antibody that is directed against the human cell surface receptor PD-1, is a PD-1 pathway... 
Physiological aspects | Genetic aspects | Research | T cells | Lung cancer, Non-small cell | Drug therapy
Journal Article
Long Range Planning, ISSN 0024-6301, 2010, Volume 43, Issue 2, pp. 364 - 369
A ‘business model’ is commonly seen as composed of two elements: a business system and a profit model. While the latter often gains the higher profile, the... 
Journal Article